Dissimilar In Vitro and In Vivo Effects of Ellagic Acid and Its Microbiota-Derived Metabolites, Urolithins, on the Cytochrome P450 1A1

被引:68
|
作者
Gonzalez-Sarrias, Antonio [1 ]
Azorin-Ortuno, Maria [1 ]
Yanez-Gascon, Maria-Josefa [1 ]
Tomas-Barberan, Francisco A. [1 ]
Garcia-Conesa, Maria-Teresa [1 ]
Espin, Juan-Carlos [1 ]
机构
[1] CSIC, CEBAS, Dept Food Sci & Technol, Res Grp Qual Safety & Bioact Plant Foods, Murcia, Spain
关键词
Pomegranate; CYP1A1; cancer; glucuronosyltransferases; sulfotransferases; Caco-2; colon mucosa; xenobiotic metabolism; POMEGRANATE JUICE; CACO-2; CELLS; COLONIC MICROFLORA; COLORECTAL-CANCER; POTENTIAL ROLE; EXPRESSION; FLAVONOIDS; INDUCTION; PUNICALAGIN; CYP3A;
D O I
10.1021/jf900725e
中图分类号
S [农业科学];
学科分类号
09 ;
摘要
This research shows that the dietary polyphenol ellagic acid (EA) and its colonic metabolites, urolithin-A (3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one, Uro-A) and urolithin-B (3-hydroxy-6H-dibenzo[b,d]pyran-6-one, Uro-B), modulate phase I and phase II detoxifying enzymes in colon cancer Caco-2 cells. EA and the urolithins, at micromolar concentrations achievable in the colon from the diet, induced the expression and activity of CYP1A1 and UGT1A10 and inhibited several sulfotransferases. As a result, the synthesis of glucuronides was favored over sulfated conjugates in the treated cells. In situ exposure to these compounds dissolved in buffer also led to the induction of CYP1A1 in the rat colon. However, in situ exposure to the compounds dissolved in oil or oral supplementation of the single compounds or pomegranate extract (PE) added to the feed failed to induce CYP1A1 in the colon mucosa. These results suggest that EA and urolithins may exert some blocking chemopreventive effects in the colon but that this effect is critically affected by interfering factors, such as the food matrix nature.
引用
收藏
页码:5623 / 5632
页数:10
相关论文
共 50 条
  • [31] The effect of cytochrome b5 on a reaction cycle of cytochrome P450 1A1
    Indra, R.
    Milichovsky, J.
    Moserova, M.
    Arlt, V. M.
    Stiborova, M.
    TOXICOLOGY LETTERS, 2015, 238 (02) : S286 - S286
  • [32] In Vitro and In Vivo Effect of Xylopic Acid on Cytochrome P450 Enzymes
    Agbenyeku, Mary A.
    Appiah-Opong, Regina
    Obese, Ernest
    Biney, Robert P.
    Adakudugu, Emmanuel A.
    Forkuo, Arnold D.
    Osei, Silas A.
    Abeka, Mustapha K.
    Ameyaw, Elvis O.
    ADVANCES IN PHARMACOLOGICAL AND PHARMACEUTICAL SCIENCES, 2022, 2022
  • [33] Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line
    Krusekopf, S
    Kleeberg, U
    Hildebrandt, AG
    Ruckpaul, K
    XENOBIOTICA, 1997, 27 (01) : 1 - 9
  • [34] Cytochrome p450 1A1 expression in cetacean integument: Implications for detecting contaminant exposure and effects
    Angell, CM
    Wilson, JY
    Moore, MJ
    Stegeman, JJ
    MARINE MAMMAL SCIENCE, 2004, 20 (03) : 554 - 566
  • [35] Modulation of cytochrome P450 1A (CYP1A) enzymes by monomethylmonothioarsonic acid (MMMTAV) in vivo and in vitro
    El-Ghiaty, Mahmoud A.
    Alqahtani, Mohammed A.
    El-Kadi, Ayman O. S.
    CHEMICO-BIOLOGICAL INTERACTIONS, 2023, 376
  • [36] Interactions among NADPH-cytochrome P450 reductase, P450 1A1, and P4502B4
    Backes, WL
    Cawley, GF
    FASEB JOURNAL, 1999, 13 (05): : A811 - A811
  • [37] Enzyme-inducing effects of berberine on cytochrome P450 1A2 in vitro and in vivo
    Jiang, Bo
    Meng, Liyuan
    Zhang, Feng
    Jin, Xiaoling
    Zhang, Guiliang
    LIFE SCIENCES, 2017, 189 : 1 - 7
  • [38] Distribution and induction of cytochrome P450 1A1 and 1A2 in rat brain
    Morse, DC
    Stein, AP
    Thomas, PE
    Lowndes, HE
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 1998, 152 (01) : 232 - 239
  • [39] Natural furocoumarins as inducers and inhibitors of cytochrome P450 1A1 in rat hepatocytes
    Baumgart, A
    Schmidt, M
    Schmitz, HJ
    Schrenk, D
    BIOCHEMICAL PHARMACOLOGY, 2005, 69 (04) : 657 - 667
  • [40] Mechanism-based inhibition of human cytochrome p450 1A1 by rhapontigenin
    Chun, YJ
    Ryu, SY
    Jeong, TC
    Kim, MY
    DRUG METABOLISM AND DISPOSITION, 2001, 29 (04) : 389 - 393